(ASRT) Assertio Holdings, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ASRT) Assertio Holdings, Inc. Complete Analysis Pack
Validate Every Claim with the Complete Sources File
This Assertio Holdings, Inc. SWOT Analysis provides a concise, company-specific breakdown of strengths, weaknesses, opportunities, and threats to support research, strategy, or investment decisions; the page includes a real preview/sample so you can review style and substance before buying. Purchase the full version to receive the complete, ready-to-use analysis instantly.
Strengths
5 marketed branded therapies
Assertio Holdings, Inc. has 5 marketed branded therapies: INDOCIN, CAMBIA, Zipsor, SPRIX, and Otrexup. That five-brand base spreads revenue across acute and chronic care, so the Company is not tied to one drug. It also gives management more room to shift focus as product demand changes.
3 therapeutic domains
Assertio Holdings, Inc. spans 3 therapeutic domains: neurology, hospital care, and pain and inflammation. That mix lowers reliance on any one disease area and lets it reach multiple prescriber settings and care pathways. In FY2024, the company reported net revenues of $141.6 million, showing this broader footprint can still support scale.
4 differentiated delivery formats
Assertio Holdings, Inc. has 4 delivery formats: oral solution, suppository, intranasal, and auto-injector. That mix can make dosing easier for different patients and care settings, from home use to acute care. Dosage-form differentiation also helps support branded positioning versus single-format rivals.
INDOCIN for 6 conditions
INDOCIN’s strength is its six labeled uses: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, gouty arthritis, and acute flare-ups. That broad footprint lets Company Name serve multiple pain and inflammation needs with one brand, which supports repeat prescribing. It also keeps INDOCIN relevant across several musculoskeletal and inflammatory conditions.
- Six FDA-labeled indications
- One brand, multiple use cases
- Broad relevance in inflammation care
31-year company history
Assertio Holdings, Inc. was incorporated in 1995 and rebranded in 2020, giving it 31 years of operating history in 2026. That long run points to experience in specialty pharmaceutical commercialization, where launch execution and payer access matter. It can also help build physician familiarity and institutional credibility over time.
- Founded in 1995
- Rebranded in 2020
- 31-year operating history in 2026
- Supports market trust and familiarity
5 Brands, 4 Formats, $141.6M Revenue: Assertio’s Scale
Assertio Holdings, Inc. has 5 marketed brands and 4 delivery formats, so revenue is less exposed to any one drug or dose form. INDOCIN adds reach with 6 FDA-labeled uses across rheumatoid arthritis, osteoarthritis, gout, and other pain needs. Its 31-year operating history and FY2024 net revenues of $141.6 million support market credibility and scale.
| Strength | Data |
|---|---|
| Brands | 5 |
| Delivery formats | 4 |
| INDOCIN labeled uses | 6 |
| FY2024 net revenues | $141.6 million |
What is included in the product
Detailed Word Document
Outlines the strengths, weaknesses, opportunities, and threats of Assertio Holdings, Inc.
Editable Excel File
Gives a clear, fast SWOT snapshot to ease strategic planning and decision-making.
Reference Sources
Lists primary, reputable sources backing market, pricing, and competitive assumptions for fast verification and defensible decision-making.
Weaknesses
4 of 5 products are NSAIDs
Four of Assertio Holdings, Inc. five core products are NSAIDs: INDOCIN, CAMBIA, Zipsor, and SPRIX. That means 80% of the portfolio sits in one drug class, which raises exposure to class-wide safety warnings, generic pressure, and demand swings. It also limits therapeutic spread, so one setback can hit a large share of revenue.
1 non-NSAID product
Otrexup is Assertio Holdings, Inc.'s only non-NSAID product, while the rest of the marketed portfolio is tied to NSAIDs. That leaves just 1 mechanism outside pain and inflammation, so the business has little balance if NSAID demand softens. In 2025-2026, that concentration keeps revenue more exposed to one drug class than peers with broader mixes.
Narrow specialty portfolio
Assertio Holdings, Inc. relies on a very small set of commercial assets, so its revenue base is concentrated. In FY2025, that kind of 3-to-5 brand mix leaves little cushion if one product weakens, faces competition, or gets a label change. One miss can hit the whole portfolio fast.
Legacy branded medicines
Assertio Holdings, Inc. still leans on legacy branded medicines, so growth is tied to mature products rather than fresh launches. That matters because mature brands usually grow slower and face higher generic pressure, which can cap revenue unless the Company Name gets label expansion or new assets. In 2025, that mix kept top-line growth harder to scale.
- Mature brands = slower growth
- Generic pressure can erode sales
- Needs launches or label expansion
Safety and monitoring burden
Assertio Holdings, Inc. faces a real safety and monitoring drag because its NSAID and methotrexate products carry serious GI, renal, hepatic, and dosing risks. Both need careful labeling, patient selection, and follow-up, which narrows eligible patients and can slow prescribing.
That burden raises commercial friction: more clinician time, more monitoring costs, and more reluctance in higher-risk patients.
- NSAID risk limits broad use
- Methotrexate needs tight monitoring
- Safety rules slow prescribing
- Eligible patient pool shrinks
Assertio’s Narrow NSAID Mix Raises Concentration Risk
Assertio Holdings, Inc. remains highly concentrated: 4 of 5 core products are NSAIDs, so about 80% of the portfolio sits in one risk bucket. That makes the Company Name vulnerable to class-wide safety, generic, and demand shocks.
Its only non-NSAID brand is Otrexup, so the mix is still narrow in 2025-2026. Mature brands and safety-heavy labels also limit growth and widen prescribing friction.
| Weakness | Latest data | Why it matters |
|---|---|---|
| Product concentration | 4 of 5 core products | 80% NSAID exposure |
| Therapeutic breadth | 1 non-NSAID product | Low mix balance |
What You See Is What You Get
Assertio Holdings, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version with in-depth insights on Assertio Holdings, Inc.
Opportunities
CAMBIA in migraine care
CAMBIA can win share because it treats migraine pain and common symptoms like nausea, photophobia, and phonophobia. Migraine affects about 1 billion people worldwide and is a top cause of disability, with about 39 million U.S. patients. Better diagnosis, access, and prescribing can support more CAMBIA use in a recurring treatment market.
Otrexup in rheumatoid arthritis
Otrexup addresses severe, active rheumatoid arthritis in adults and active polyarticular juvenile idiopathic arthritis in children, both long-duration specialty markets with repeat treatment needs. Rheumatoid arthritis affects about 18 million people worldwide, and JIA impacts roughly 1 in 1,000 children, supporting a durable patient pool. Its single-dose auto-injector can improve convenience and adherence, which may help adoption.
SPRIX in short-term pain
SPRIX gives Assertio Holdings, Inc. a niche in moderate to moderately severe pain, with opioid-level analgesia from a non-opioid product. The U.S. still sees more than 8 million opioid prescriptions a month, so demand for alternatives stays real. Hospital and post-acute use can widen adoption when clinicians want fast pain control without an opioid.
Portfolio lifecycle expansion
Assertio Holdings, Inc. can stretch its 5 marketed products through label changes, new use cases, and channel expansion, which is often cheaper than launching new drugs. That matters because the company is still scaling a smaller base, with 2024 net revenue of about $146 million, so even modest label wins can move results. Existing brands can also get more value from access work, where better payer coverage can lift volume without major R&D spend.
- 5 marketed products create low-cost expansion paths
- Label and access gains can lift sales faster
- Channel expansion can add value without new assets
Hospital-care demand
Assertio already has hospital-care exposure, so it can sell into a setting that still needs non-opioid, specialty pain options. U.S. hospital spending remains huge, at about $1.5 trillion in 2025, and providers keep pushing to cut opioid use while keeping pain control strong.
- Hospital demand favors differentiated analgesics.
- Non-opioid use is still a key need.
- Clear clinical utility can support uptake.
That gives Assertio a direct path if its products show faster recovery, fewer safety issues, or simpler use in inpatient care. In this market, proof matters more than price.
Assertio Can Grow Fast Through Label, Access, and Channel Gains
Assertio Holdings, Inc. can grow by pushing label expansion, access wins, and channel reach across its 5 marketed products, a low-cost path for a company with about $146 million in 2024 net revenue. Even small share gains can matter.
| Opportunity | Data point |
|---|---|
| Portfolio expansion | 5 marketed products |
| Revenue base | About $146M net revenue |
| Large pain markets | Migraine, RA, hospital pain |
CAMBIA, Otrexup, and SPRIX each target recurring or specialty use where better diagnosis, payer coverage, and non-opioid demand can lift volume.
Threats
4 NSAID brands face class competition
Most of Assertio Holdings, Inc.’s revenue still comes from NSAID brands, so one class-wide price war can hit several products at once. That matters because NSAIDs face heavy branded and generic competition, with dozens of low-cost ibuprofen and naproxen options on the market, which keeps pricing power weak. If payer pressure or generic substitution rises, volume and margins can slip across the portfolio at the same time.
NSAID safety restrictions
NSAID safety restrictions are a clear threat for Assertio Holdings, Inc.: labels already warn of serious gastrointestinal bleeding, heart attack, stroke, and kidney injury. Even small tightening can cut use fast, since U.S. NSAID safety warnings are class-wide and payer step edits often favor lower-risk options. That pressure can hit volume and pricing, especially in chronic pain products like INDOCIN and Otrexup.
Methotrexate monitoring risk
Otrexup depends on once-weekly methotrexate, so patients need tight CBC, liver, and kidney monitoring to avoid serious toxicity. That clinical burden can slow switching from established injectables, especially when adverse events like marrow suppression or hepatotoxicity are a concern. Pediatric and adult specialists are often cautious, which can limit uptake and keep prescribing slow.
Reimbursement pressure
Reimbursement pressure remains a key threat for Assertio Holdings, Inc., because specialty drugs often face payer scrutiny, step edits, and formulary limits that cut net sales. In 2025, Assertio reported net sales of $145.1 million, showing how a smaller branded portfolio can feel each rebate or access shift. Any tighter contracting can quickly compress margins and slow volume growth.
- Payer access can block prescriptions.
- Rebates lower net realized sales.
- Smaller firms face more pricing pressure.
Therapeutic substitutes
Therapeutic substitutes are a real threat for Assertio Holdings, Inc. in migraine, pain, and inflammatory disease, where prescribers can choose from many branded drugs, generics, and device-led options. In migraine alone, the market spans CGRP therapies and oral generics, while pain care faces heavy generic erosion, so switching can happen fast when price or efficacy changes.
That pressure can weaken brand loyalty across Assertio Holdings, Inc.'s portfolio and compress margins if payers push cheaper alternatives or newer delivery formats.
- Many substitutes across key therapy areas
- Generics and newer mechanisms raise switching risk
- Payer pressure can cut pricing power
Assertio Faces Payer and Generic Pressure as Sales Stay Under Strain
Assertio Holdings, Inc. still faces heavy payer and generic pressure, and 2025 net sales of $145.1 million show how quickly access shifts can hit a small portfolio. NSAID safety limits and class-wide competition can cut demand, while cheaper substitutes in pain and migraine keep pricing power weak.
| Threat | Latest data |
|---|---|
| Payer pressure | 2025 net sales: $145.1 million |
| Generic substitution | Multiple low-cost NSAID options |
| Safety risk | Class-wide NSAID warnings |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.